Reading
Start with the label for the named use and cautions. Read a treatment study to see what changed in the people taking part.
HIV means human immunodeficiency virus; lipodystrophy means a changed pattern of body fat.
As of September 2026, the approved use is excess belly fat for adults who have HIV and lipodystrophy.
In the U.S., medicines are reviewed by an agency called the Food and Drug Administration (FDA).
The labels also cover the cautions and the checks that belong in a care discussion.
SV and WR name two versions of tesamorelin with different doses; the labels say they cannot be swapped.
DailyMed: tesamorelin (EGRIFTA WR) labelDailyMed: tesamorelin (EGRIFTA SV) labelFDA: tesamorelin approval recordPlacebo is a dummy treatment used as the comparison.
The Falutz paper published in 2007 studied 412 adults with HIV and excess belly fat for 26 weeks.
It reported deep belly fat falling by 15.2% with tesamorelin, while the placebo group’s deep fat rose by 5.0%.
PubMed: the earlier Falutz studyThe Falutz paper published in 2010 studied 404 adults with HIV and excess belly fat.
At six months, the tesamorelin group’s deep belly fat was down 10.9%, compared with a 0.6% fall in the placebo group.
PubMed: the later Falutz studyThese are group results for the people studied. They are not a personal forecast.
People switched to placebo regained deep belly fat during the later part of the studies.
PubMed: the combined study resultsA liver-fat study published in 2019 included 61 people with HIV and lasted 12 months.
Liver fat fell more with tesamorelin than with the dummy treatment.
As of September 2026, these small studies do not make liver-fat treatment an approved tesamorelin use.
PubMed: the liver-fat studyThe research reviewed in September 2026 gave mixed results for thinking and memory.
PubMed: the older-adult thinking studyPubMed: the HIV thinking studyPreparation to order is what the word compounding describes.
Tesamorelin is a biologic, a legal category that includes protein medicines.
U.S. law in September 2026 does not permit pharmacy compounding of this category of medicines.
FDA: compounding questions and answersFederal regulation: the protein definitionDoctors’ licences and actions against them are documented in state medical boards’ public records.
Their shared group, the Federation of State Medical Boards, publishes advice about care by video, phone or online messages.
State boards receive this as guidance; it is not a law in force everywhere.
State boards’ advice: care over a screenState boards’ advice: prescriptions and pharmacy supplyFederal health guidance: where licences applyCheck a doctor’s licence through the relevant state medical board’s record; boards differ in the details they publish.
Medical boards: find the board for your stateFDA’s lookup links to pharmacy licence records by state.
FDA: find the pharmacy licence lookupFDA: checking the signs of an online pharmacyMedlinePlus: severe allergic reactionsIn September 2026, the maker’s pages did not give a public tesamorelin price, and no government-published price was found.
Ask for the exact medicine quote and full assistance terms when discussing care. A plan-specific coverage answer belongs with that quote.
Maker: patient support and help with medicine costsReturn to the cost questionsWeighing care for deep belly fat
Keep each claim tied to its source, its date and the people it describes.